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ARIEL L. BARKAN, MD 
The adverse gastrointestinal effects of octreotide, a synthetic analog of somatostatin, 
have not been fully elucidated. Low-dose octreotide frequently causes adverse gastroin- 
testinal symptoms in normal individuals. We investigated the adverse gastrointestinal 
effects of high-dose octreotide, which is required for the normalization of growth hormone 
hypersecretion in some patients with acromegaly. Patients with acromegaly (N = 8) were 
treated with octreotide, 450 tzg/day, then 1500 t~g/day for two months at each dosage. 
Carbohydrate absorption was assessed using the D-xylose test, and fat absorption using 
fecal fat excretion and serum carotene concentrations, at baseline, at each dosage of  
octreotide, and after one month of washout. Ultrasonography was used to monitor for 
cholelithiasis. Growth hormone and insulin-like growth factor-I concentrations were 
significantly suppressed at both dosages. Adverse gastrointestinal symptoms were mild 
and transient. D-Xylose absorption remained normal at each dosage and after one month 
of washout. Fecal fat excretion increased from 7 4- 2 to 12 +- 2 g/24 hr (P < 0.05) after the 
higher dosage and resumed baseline levels after the washout. Mean fasting serum 
carotene levels remained normal, and carotene loading test (15,000 units three times a day 
for three days) was unreliable in identifying patients with high fecal fat. No new 
cholelithiasis was detected by ultrasonography. One of two patients with preexisting 
cholelithiasis developed biliary colic several days after the treatment period. Although 
steatorrhea was common, small intestinal absorptive capacity was otherwise unchanged 
by four months of high-dose octreotide treatment, which significantly suppressed growth 
hormone secretion in acromegalic patients. 
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East Hanover, New Jersey) is a synthetic octapep- 
tide analog of the native hormone somatostatin, 
which is widely distributed in the body and has 
effects upon various systems (1, 2). Octreotide has 
been shown to reduce growth hormone (GH) hyper- 
secretion in patients with acromegaly (3), as well as 
the symptoms of malignant carcinoid syndrome and 
VIPoma (4). To date it has been approved by the 
Food and Drug Administration for use for the latter 
two indications, while its use for other conditions is 
still under investigation. In particular, certain po- 
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tential adverse effects of the drug have yet to be 
defined. 
Previous studies have shown that administration 
of octreotide produces a variety of  adverse gastro- 
intestinal effects (4, 5), which mimic those found in 
patients with somatostatinomas, such as diarrhea, 
steatorrhea, and formation of  biliary stones (6). The 
aim of  this study was to investigate whether chronic 
treatment with high doses of  octreotide over four 
months caused malabsorption in patients with ac- 
romegaly, as measured by D-xylose absorption, fe- 
cal fat excretion, and serum carotene concentra- 
tions. 
MATERIALS AND METHODS 
Patients. The study group consisted of eight patients 
(five males, three females, 23-60 years of age) with active 
acromegaly. Earlier safety studies have shown that ad- 
verse gastrointestinal symptoms occur commonly in nor- 
mal individuals at relatively low doses of octreotide. In 
contrast, patients with acromegaly require chronic ther- 
apy and sometimes at high doses (600-1500 p.g/day) in 
order to suppress their growth hormone and insulin-like 
growth factor-I (IGF-I) concentrations. Thus, this group 
of patients was chosen because they would require higher 
doses of octreotide and would benefit from this protocol 
by normalization of GH secretion. All patients had been 
treated for acromegaly previously: transsphenoidal or 
transfrontal craniotomy in all, radiotherapy in six pa- 
tients, and bromocriptine for up to 11 years in six pa- 
tients. Bromocriptine was ceased 2-12 months prior to 
this study. All patients had also been treated with oc- 
treotide, and it had been stopped one month to three 
years prior to this study. Five patients were included in a 
previous report on the effect of octreotide on GH secre- 
tion in acromegaly (3). The diagnosis of active acrome- 
galy was reconfirmed before commencement of this study 
clinically and by high plasma GH and IGF-I concentra- 
tions. Three patients (#5, 7, and 8) had intact pituitary 
function and the other five patients had hypopituitarism, 
which was treated with appropriate replacement therapy. 
Patients 5 and 6 had non-insulin-dependent diabetes 
controlled with diet and oral hypoglycemic agents. Pa- 
tient 8 had previously been treated for Graves disease and 
had been euthyroid without thyroxine supplement for 
several years. None had any significant hepatic disease. 
Patients 3 and 7 had asymptomatic cholelithiasis. Patient 
5 had morbid obesity and had undergone reduction gas- 
troplasty and prophylactic cholecystectomy seven years 
previously. All had a history of normal and formed bowel 
movements (once every one or two days), and none were 
taking medications known to affect gastrointestinal func- 
tion. 
Protocol. The protocol was approved by the local In- 
stitutional Review Board and written informed consent 
was obtained from every patient. Octreotide was self- 
administered subcutaneously by the patients. Studies 
were performed four times: at baseline, after octreotide 
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was administered at 150 ~g three times a day for nine 
weeks, after the dose was escalated to 250 txg three times 
a day for two weeks followed by 500 Ixg three times a day 
for six weeks, and finally after a five-week washout pe- 
riod. 
At every visit, a detailed clinical history was taken, 
with specific emphasis on the gastrointestinal system. 
Patients were asked whether their bowel movements in- 
creased in frequency but had unchanged consistency, had 
unchanged frequency but became soft or loose, or there 
was a combination of both soft or loose stools together 
with the increased frequency of bowel movements (diar- 
rhea). Standard biochemical and hematologic analyses, 
thyroid function tests, glycosylated hemoglobin, plasma 
IGF-I, and serum GH concentrations were measured 
after an overnight fast. Blood was drawn for GH hourly 
for 5 hr (0800-1300 fir) at baseline and at the postwashout 
visit. At the two visits when patients were taking oc- 
treotide, the first blood sample was drawn immediately 
before the drug was administered at 0800 hr, and then 
hourly samples were drawn from 1000 to 1400 hr. 
At every visit, the D-xylose testing was performed. 
Patients ingested 25 g D-xylose (Adria, Columbus, Ohio) 
in 500 ml water immediately after emptying the bladder in 
the morning after an overnight fast. Plasma xylose con- 
centration was measured immediately before, and at 30, 
60, and 120 min after ingestion of D-xylose. Urine was 
collected over 5 hr following the ingestion for measure- 
ment of urinary xylose excretion and calculation of cre- 
atinine clearance. During the test, patients were allowed 
to ingest water ad libitum only. At the two visits when 
patients were taking octreotide, D-xylose was ingested 1 
hr after the injection of octreotide. 
Fecal fat excretion was measured using a 72-hr fecal 
collection prior to each visit. Patients consumed 100 g fat 
per day for three days prior to and during the collection 
period. Fasting serum carotene concentration was mea- 
sured at each visit. At the end of the high-dose treatment 
period (with octreotide 500 ~g three times a day), fasting 
serum carotene concentration was also measured after 
three days of [3-carotene (Freeda Vitamins, New York, 
New York) 15,000 units three times a day with meals 
while maintaining 100 g per day fat consumption. Com- 
pliance with fat consumption was confirmed by the pa- 
tients' written food records. Upper abdominal ultrasound 
examination was performed at baseline and during low- 
and high-dose octreotide treatment to monitor for gall- 
stones and was repeated after the washout period in any 
patient who had gallstones detected earlier. 
IGF-I was assayed by Smith-Kline Laboratories (Van 
Nuys, California) using the method of Furlanetto et al (7). 
Fecal fat was assayed by Mayo Clinic Laboratories 
(Rochester, Minnesota) using a gravimetric method (8, 9). 
All other biochemical measurements were done by Met- 
path Laboratories (Teterboro, New Jersey). GH was as- 
sayed by double antibody RIA (10). Plasma and urinary 
xylose were assayed spectrophotometrically (11). Serum 
carotene was assayed by spectrophotometrically (12). 
Data were analyzed by analysis of variance with re- 
peated measures. Data are shown as mean --- SE. Statis- 
tical significance was assessed at P < 0.05. 
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RESULTS 
Serum GI-I and Plasma IGF-I Concentrations. 
Mean GH concentrations were elevated at 12.8 - 
3.4 ~g/liter (normal < 4.5 ~g/liter) at baseline. Mean 
GH for the whole group decreased significantly to 
4.0 + 0.7 ~g/liter at nine weeks of treatment with 
octreotide 150 Ixg three times a day, but did not fall 
further after another eight weeks of treatment at 500 
~g three times a day (3.7 --- 0.8 p,g/liter). Five weeks 
after cessation of the drug, mean GH concentra- 
tions rose significantly to 13.1 --- 4.5 ixg/liter, which 
was similar to the baseline value. Plasma IGF-I 
concentrations (normal -< 318 ~g/liter in men, -< 270 
txg/liter in women) showed the same pattern of 
changes (baseline: 882 --- 95; 150 ~g three times a 
day dose: 472 --- 59; 500 Ixg three times a day dose: 
389 - 65; and five weeks postwashout: 861 --+ 78 
txg/liter. 
Adverse Symptoms. All patients experienced gas- 
trointestinal side effects during treatment with oc- 
treotide, namely abdominal gas (seven patients), 
transient nausea postinjection (three patients), soft 
stools of unchanged frequency (three patients), in- 
creased frequency of bowel movements (one pa- 
tient from one bowel movement every other day to 
one to two formed stools every day) and diarrhea 
(two patients, five to seven bouts per day). In most 
cases, the symptoms were present transiently (up to 
two days) at the start of the study, or when the dose 
of octreotide was escalated, while in others the 
symptoms decreased but lasted for the entire treat- 
ment period. One patient took 200 Ixg three times a 
day instead of 150 txg three times a day at the 
beginning of the study. He experienced severe ab- 
dominal gas and diarrhea, which persisted until the 
dosage was decreased to the originally prescribed 
150 txg three times a day several days later. When 
the dosage was increased to 500 txg three times a 
day, he experienced the same symptoms, which 
subsided when the dose was reduced to 450 txg 
three times a day, which was the final dosage in this 
patient, in the other seven patients no side effects 
were severe enough to require a decrease in the 
dose of octreotide at any time, and the highest dose 
taken was 500 ~g three times a day. All symptoms 
disappeared within one to two days of stopping the 
drug on completion of the treatment protocol by all 
patients. Fecal weight (72 hr collection) at baseline 
was 338 --- 82 g; after octreotide 150 ~g three times 
a day it was 451 • 92 g; after 500 p,g three times a 
day, 472 -+ 109 g; and after one month of washout, 
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Fig 1. Assessment of fat absorption in eight patients with ac- 
romegaly before and after treatment with octreotide at 150 wg 
three times a day and 500 I~g three times a day for two months at 
each dose, and after a one-month washout. Normal ranges are 
shown by the shaded areas. *P < 0.05 vs baseline, t P  < 0.05 vs 
500 wg three times a day. 
305 --- 58 g. No difference between the time points 
was detected using ANOVA with repeated mea- 
sures. 
Fecal Fat Excretion and Serum Carotene Concen- 
trations. At baseline, fecal fat excretion (Figure la) 
was elevated in patients 1 and 2 (9 and 16 g/24 hr, 
normal 2-7 g/24 hr). Both patients had not been 
taking octreotide for 0.7 years prior to this study. 
The mean for the entire group was at the upper limit 
of normal range (6.6 - 1.7 g/24 hr). When octreotide 
was administered at 150 Ixg three times a day, an 
additional three patients had elevated fecal fat ex- 
cretion, and the mean fecal fat excretion rose to 9 --- 
2 g/24 hr, although this was not statistically signifi- 
cant. When octreotide was taken at high dose (500 
Ixg three times a day) a total of six patients had 
elevated fecal fat excretion, and the mean fecal fat 
excretion (11 + 2  g/24 hr) for the entire group was 
significantly higher (P < 0.05) than the baseline 
value. After the five-week washout, only patients 1 
and 6 had elevated fecal fat excretion (10 and 16 
g/24 hr) and the mean value for the whole group (6 
+- 2 g/24 hr) was similar to the baseline. 
Fasting serum carotene concentration (Figure Ib) 
at baseline was mildly decreased in two patients 
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Fig 2. Plasma D-xylose concentration (a) and urinary D-xylose excretion (b) in eight 
patients with acromegaly during D-xylose test performed before and after treatment 
with octreotide 150 ~g three times a day and 500 Ixg three times a day for two months 
at each dose, and after a one-month washout. Normal ranges are shown by the 
shaded areas. (a) [], baseline; 9 after two months of octreotide 150 ~g three times 
a day; A, after another two months of octreotide 500 ~g three times a day; ~, after 
one month of washout. 
(0.80 and 0.85 txmol/liter, normal 0.93-4.70 ~mol/ 
liter) and normal in the other six patients. When 
octreotide was taken at a low dose (150 ~g three 
times a day), four of  the eight patients had mildly 
decreased fasting serum carotene concentrations 
(0.82-0.89 i~mol/liter), but at a high dose (500 Ixg 
three times a day) only two had decreased values 
(0.85 ~mol/liter in both). After washout,  serum car- 
otene concentrat ion was normal in every patient. 
Mean serum carotene concentrat ion for the entire 
group was statistically unchanged with octreotide 
treatment (1.40 --- 0.19 at baseline, 1.18 +-- 0.28 and 
1.13 --- 0.08 ixmol/liter at octreotide 150 ~g three 
times a day and 500 ~xg three times a day, respec- 
tively) as well as after the five-week washout (1.40 
--- 0.08 txmol/liter). Three patients exhibited a sub- 
normal rise of  serum carotene (0.22-0.32 ~xmol/liter, 
normal - 0.65 ixmol/liter) postcarotene loading at 
the end of the high-dose treatment period, but only 
two of  them had increased fecal fat (9 and 18 g/24 
hr). 
o-Xylose Absorption. Plasma D-xylose concentra- 
tions during the D-xylose test were within the nor- 
mal range throughout  the study (Figure 2a). Urinary 
xylose excret ion over  5 hr after xylose ingestion 
(Figure 2b) was normal at baseline (5.8 --- 0.8 g) and 
unchanged with octreotide treatment (6.6 --- 0.6 and 
5.8 --- 0.4 g at octreotide 150 Ixg three times a day 
and 500 ~g three times a day, respectively),  as well 
as after the five-week washout (6.9 - 0.7 g). At no 
instance did urinary D-xylose excretion decline to a 
subnormal range. Creatinine clearance was normal 
at baseline (2.22 --- 0.23 ml/sec) and unchanged with 
octreotide treatment (2.08 --- 0.20 and 2.08 --- 0.23 
ml/sec, with octreotide 150 ~g three times a day and 
500 ~xg three times a day, respectively),  as well as 
after the five-week washout  (2.12 --- 0.23 ml/sec). 
Cholelithlasis .  Serial upper  abdominal ultrasound 
examination showed no changes from baseline in 
patients 3 and 7, who had cholelithiasis at baseline, 
or in the other  five patients who remained without 
gallstones during the t reatment  period. Patient 3 
had a bout  of biliary colic five days after octreotide 
had been ceased and underwent  elective cholecys- 
tec tomy 10 days later. 
Serum Biochemistry. Mild to moderate  hyper-  
phosphatemia was present  in six patients at baseline 
(1.39-1.71, normal 0.71-1.36 mmol/liter), in two 
(1.45 and 1.58 mmol/liter) when treated with oc- 
treotide 150 I~g three times a day, in three (1.39- 
1.45 mmol/liter) with 500 Ixg three times a day, and 
in five (1.45-1.58 mmol/liter) after washout.  Serum 
inorganic phosphate concentrat ion for the entire 
group decreased from 1.42 --- 0.06 mmol/liter at 
baseline to 1.26 --- 0.06 mmol/liter (P < 0.05) when 
octreotide was taken at 150 ~g three times a day and 
remained at the same level during the higher dosage 
of  octreotide. After the washout  it increased (P < 
0.05) to the baseline value (1.46 --- 0.06 mmol/liter). 
Serum calcium, protein, albumin, alkaline phospha- 
tase,  alanine amino t ransferase ,  and aspar ta te  
amino transferase concentrat ions were normal and 
stable throughout the protocol.  In patient 6, who 
had non-insulin-dependent diabetes mellitus, both 
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fasting serum glucose concentrations (baseline: 14.2 
mmol/liter, 150 fxg three times a day dose: 6.6 
mmol/liter, 450 txg three times a day dose: 8.3 
mmol/liter) and glycosylated hemoglobin (baseline: 
9.5%, 150 txg three times a day dose: 8.7%, 450 p~g 
three times a day dose: 6.2%) decreased with oc- 
treotide treatment and rose towards baseline levels 
after the washout (15.3 mmol/liter and 7.7%, re- 
spectively). In patient 5, glycosylated hemoglobin 
improved slightly with high-dose (500 ~g three 
times a day) but not with low-dose (150 txg three 
times a day) octreotide (baseline: 10.2%, 150 ~g 
three times a day dose: 10.4%, 450 Ixg three times a 
day dose: 9.4%), and fasting serum glucose concen- 
trations (baseline: 11.6 mmol/liter, 150 ~g three 
times a day dose: 10.1 mmol/liter, 450 ixg three 
times a day dose: 14.3 mmol/liter) were essentially 
unchanged or higher at the two different doses, 
respectively. After the washout, glycosylated he- 
moglobin was 10.4%, similar to baseline, and fast- 
ing serum glucose concentration was 14.5 mmol/ 
l i ter  in this pa t ien t .  Fo r  the ent i re  group,  
glycosylated hemoglobin and thyroid function tests 
(total and free thyroxine, and thyroid stimulating 
hormone) remained normal and unchanged through- 
out the study. Routine hematologic analyses were 
normal throughout the study. 
DISCUSSION 
The natural hormone and neurotransmitter so- 
matostatin is widely distributed in the body, includ- 
ing the hypothalamus, nervous system, and gastro- 
intestinal  tract .  Its inhibitory action affects 
endocrine, exocrine, as well as neurological func- 
tions (1, 2). The application of somatostatin to the 
treatment of disorders involving hyperfunction of 
its target organs has been limited by its lack of 
specificity and short half-life, and a rebound of the 
processes inhibited on cessation of somatostatin 
infusion. These problems have been largely over- 
come by the development of the somatostatin ana- 
log octreotide (13). Octreotide is approved by the 
Food and Drug Administration for treatment of the 
symptoms of malignant carcinoid syndrome and 
VIPoma. Its use in other diseases such as acrome- 
galy, thyrotropin-producing pituitary tumors, and 
some nonmalignant diseases of the gut (4) is still 
experimental. Certain adverse effects have yet to be 
elucidated. 
Previous studies have shown that, overall, oc- 
treotide is well tolerated and major side effects are 
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rare. The more common side effects involve the 
gastrointestinal tract. Studies in normal individuals 
and patients have shown that mild transient abdom- 
inal bloating, gas, and cramping occur frequently 
during the initial days to weeks of treatment (4, 5), 
which is similar to the present study. The initial 
adverse symptoms decreased to easily tolerable lev- 
els with continuing octreotide therapy at the same 
dose in all but one of our patients. In that patient, 
symptoms appeared to be dose-dependent and did 
not abate until the dose was decreased, but even so, 
tolerance to the drug in terms of adverse symptoms 
was evident by their considerably milder and tran- 
sient nature when the dose was increased further 
after several more weeks of treatment. 
The biologic efficacy of octreotide and the adher- 
ence to therapy in this study were verified in each 
patient by significant declines in plasma GH and 
IGF-I levels and by improvement of hyperphos- 
phatemia and diabetic control in some subjects. 
An increase in fecal fat excretion in six of eight 
patients during administration of octreotide in this 
study is consistent with those of many past studies 
in both normal subjects and patients with acrome- 
galy (3, 5, 17), and indicates obvious fat malabsorp- 
tion. In the present study, serum carotene concen- 
tration remained normal or near normal, similar to 
an earlier study (18). The maintenance of normal 
serum calcium and alkaline phosphatase concentra- 
tions during octreotide treatment is consistent with 
normal vitamin D absorption, and with the normal 
25-hydroxy vitamin D and alkaline phosphatase 
concentrations in the earlier study (18). In the pre- 
sent study, the increase in serum carotene concen- 
tration after loading was subnormal (increment < 
0.65 ixmol/liter) in only three patients, and only two 
of them had steatorrhea (fecal fat > 7 g/24 hr). 
Thus, in contrast to an earlier study (19), we found 
that measurement of serum carotene with or with- 
out prior loading was considerably less sensitive 
and specific than quantification of 72-hr fecal fat. 
The mechanism by which octreotide causes fat mal- 
absorption in patients with acromegaly appears to 
be via a decreased secretion of and gallbladder 
sensitivity to cholecystokinin (20). Somatostatin in- 
fusion inhibits bile formation (21), and octreotide 
may also have a similar effect. Additionally, pan- 
creatic exocrine function has been shown to be 
suppressed by octreotide (22, 23) with 24 hr produc- 
tion of amylase and lipase being suppressed by 63 
and 27%, respectively. The combination of exo- 
crine pancreatic insufficiency and decreased biliary 
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function is likely to account for the gastrointestinal 
symptoms that occur in patients treated with oc- 
treotide. In support of this is the efficacy of pancre- 
atic enzyme therapy in alleviating most of the gas- 
trointestinal side effects of octreotide during the 
initial weeks of therapy (3). 
o-Xylose absorption occurs in the duodenum and 
jejunum by passive diffusion and therefore reflects 
the functional absorptive capacity of the proximal 
small intestine (16). Renal excretion accounts for 
half the total D-xylose elimination and is dependent 
on the glomerular filtration rate (24). The combina- 
tion of plasma D-xylose concentration at 1 hr, with 
5-hr urinary excretion of D-xylose after ingestion of 
a 25-g D-xylose load has been shown to be approx- 
imately 95% specific and sensitive in discriminating 
normal from subnormal proximal small intestinal 
absorption (24). Our results show that using this 
test, proximal small intestinal absorption in this 
group of patients was normal and stable during and 
after octreotide treatment, The normality and sta- 
bility of creatinine clearance in our patients vali- 
dates the use of urinary D-xylose excretion as a 
measure of o-xylose absorption and for serial com- 
parison. Our results are similar to those obtained in 
normal subjects given an intravenous bolus and 
continuous infusion of octreotide in a previous 
study (25). In contrast, a study using patients with 
acromegaly showed that peak plasma xylose con- 
centration after ingestion of D-xylose was un- 
changed by octreotide treatment, but the rise in 
plasma xylose concentration was slightly delayed 
(26). However, in that study, D-xylose was admin- 
istered with a meal rather than in the fasting state as 
was done in the present study. Since meal ingestion 
could alter D-xylose absorption (24), it is conceiv- 
able that this might explain the difference between 
the two studies. 
In the present study, shortly after four months of 
treatment at the maximal dose (1500 txg/day) of 
octreotide, one of two patients who had preexisting 
gallstones developed biliary colic necessitating 
cholecystectomy; the other remained asymptom- 
atic, and no patient developed new cholelithiasis. 
Cholelithiasis is present in up to 50% of patients 
receiving octreotide, similar to the 65% prevalence 
rate in patients with somatostatinomas (27). Gall- 
bladder contractility is impaired by somatostatin 
and was completely abolished by injection of 100 ixg 
octreotide subcutaneously prior to a meal in a group 
of patients with acromegaly who were receiving 
chronic octreotide treatment (20). Thus develop- 
ment of cholestasis and cholelithiasis may be ex- 
pected with octreotide treatment. Whether our pa- 
tients' biliary colic was precipitated by the recent 
course of octreotide cannot be verified, but the 
question of treating patients with preexisting chole- 
lithiasis with the drug needs to be addressed. 
In summary, we have shown that in this group of 
eight patients with acromegaly, adverse gastrointes- 
tinal symptoms during high-dose octreotide therapy 
were common, but most were mild and transient. 
Our results also show that fat malabsorption was 
common as detected by 72-hr fecal fat measure- 
ment, although maintenance of normal or near- 
normal serum carotene concentrations and normal 
serum calcium and alkaline phosphatase concentra- 
tions on a normal diet suggest that absorption of 
fat-soluble nutrients was probably maintained at or 
near normal levels. Measurement of serum carotene 
concentration after carotene loading was not useful 
in identifying patients with fat malabsorption. D - X y -  
lose absorption remained normal, suggesting that 
octreotide did not affect the functional absorptive 
capacity of the proximal small intestine. 
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